Mohammed Alo։ How Low Should LDL Go in Secondary Prevention of Cardiovascular Disease
Mohammed Alo, Fellow of the American College of Cardiology at American College of Cardiology, shared a post on LinkedIn:
“For years, cardiology has debated a simple question:
If you already have heart disease, how low should your LDL cholesterol go?
The new Ez-PAVE trial gives us one of the clearest answers yet.
This randomized trial followed 3,048 patients with established atherosclerotic cardiovascular disease and compared 2 LDL targets:
- LDL less than 55 mg/dL vs LDL less than 70 mg/dL
After 3 years, the lower-target group had significantly fewer cardiovascular events:
- 6.6% vs 9.7%
- Hazard ratio: 0.67
That translates to:
- 33% relative risk reduction
- 3.1% absolute risk reduction
Why does this matter?
Because this was not just a ‘drug trial.’
It was a target-to-target trial.
It asked the real-world question physicians and patients face every day:
Is aiming for below 55 actually better than aiming for below 70?
The answer appears to be yes.
A few key takeaways:
- Even a modest LDL difference mattered
- Fewer heart attacks and repeat procedures occurred in the lower-target group
- Safety was reassuring
- Many high-risk patients in the real world are still nowhere near these targets
My take as a cardiologist:
If you already have coronary disease, prior stents, bypass surgery, stroke, TIA, or peripheral artery disease, an LDL of 65 or 70 should not automatically be considered ‘good enough.’
For most secondary prevention patients, under 55 mg/dL is the right goal.
The therapies already exist:
- High-intensity statins
- Ezetimibe
- PCSK9 inhibitors when needed
The issue is no longer whether lower is better.
The issue is whether we are actually getting patients there.”

Stay updated with Hemostasis Today.
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center
-
May 29, 2026, 17:20Martin Widschwendter: How Molecular Detection Tests Could Transform Endometrial Cancer Care
-
May 29, 2026, 17:18Nina Lansbury: Supporting a Period Friendly World With Menstrual Health Research and Education
-
May 29, 2026, 17:16Ipsita Chatterjee: Red is Not Shame, Red is Power, Red is a Woman
-
May 29, 2026, 16:49Abdulrahman Nasiri: The Evolving Role of Romiplostim in SAA
-
May 29, 2026, 16:46Soumen Bhattacharya: UC-II and Immune Modulation in Osteoarthritis
-
May 29, 2026, 16:38Ana Pedrero Gil: Red Blood Cell Transfusion Practice in Spain – High Inappropriateness Despite Low Overall Use
-
May 29, 2026, 15:40Lena Volland: Expanding Holistic Care in Bleeding Disorders Through Pelvic Health Physical Therapy at WFH Congress